Compare AMBQ & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMBQ | AAPG |
|---|---|---|
| Founded | 2010 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2025 | 2024 |
| Metric | AMBQ | AAPG |
|---|---|---|
| Price | $47.76 | $14.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | ★ $87.71 | $44.50 |
| AVG Volume (30 Days) | ★ 380.2K | 4.6K |
| Earning Date | 11-10-2026 | 08-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 95.97 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $72,514,000.00 | N/A |
| Revenue This Year | $86.45 | $18.59 |
| Revenue Next Year | $31.98 | $120.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $22.12 | $14.46 |
| 52 Week High | $91.61 | $34.50 |
| Indicator | AMBQ | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 33.40 | 39.79 |
| Support Level | $32.05 | N/A |
| Resistance Level | $68.15 | $16.41 |
| Average True Range (ATR) | 3.00 | 0.48 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 6.82 | 3.91 |
Ambiq Micro Inc is a fabless semiconductor company that has developed technology based on a patented Sub-threshold Power Optimized Technology (SPOT) platform that significantly reduces the amount of power consumed by integrated circuits. It is a pioneer and provider of ultra-low power semiconductor solutions designed to address the power consumption challenges of general purpose and AI compute - especially at the edge. The company provides a full-stack solution encompassing tightly integrated hardware and software. Its solutions include a diverse family of systems-on-chip (SoCs) and the software required to enable on-chip AI processing, general compute, sensing, security, storage, wireless connectivity, and developed graphics.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.